Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Dec

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers

FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL

Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening

AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease

Survey Finds Global Embrace of Integrative Cancer Care